Select a year
allDate
Subject
File download
2025.11.19
Announcement: The company's directors and others have reached a settlement agreement with the Securities and Futures Investors Protection Center in a civil lawsuit
2024.03.25
The Board of Directors of the Company has approved the 2023 Employee Remuneration and Director Remuneration
2024.01.30
Announcement of the Company's Board of Directors' resolution to convene the 2024 Annual General Meeting of Shareholders
2023.12.06
Announcement: Our company has been fined NT$200,000 for violating the Medical Devices Administration Act
2023.11.20
Announcement: The company's board of directors has approved the change of general manager
2023.09.26
Our company's long-acting pain reliever injection, Naldebain, has obtained import drug approval from Brunei
2023.08.08
The Board of Directors of the Company hereby announces that it has approved the financial report for the second quarter of 2023
2023.07.21
Cooperating with the Taipei City Investigation Office of the Investigation Bureau, Ministry of Justice, in the investigation
2023.04.17
The Board of Directors of the Company hereby announces that it has approved the 2022 Annual Financial Report
2023.04.17
Announcement of the Company's Board of Directors' Resolution to Transfer Surplus to Capital Increase and Issue New Shares
2023.04.17
Announcement Regarding the Board of Directors' Resolution to Convene the 2023 Annual General Meeting of Shareholders (with Additional Reasons for Convening)
2023.03.13
Announcement of the Company's Board of Directors' resolution to convene the 2023 Annual General Meeting of Shareholders
2022.08.23
Our HeraDerm Scar care Dressing (non-sterile) has obtained import medical device approval from the Philippine Food and Drug Administration
2022.08.15
Correction to the Company’s Second Quarter Individual Financial Report and iXBRL Information
2022.08.08
Announcement of the Board of Directors' resolution regarding matters related to the ex-rights date in 2022
2022.08.08
The Board of Directors of the Company hereby announces that it has approved the financial report for the first half of 2022
2022.06.22
Announcement: Our company has been invited to participate in the online investor briefing for emerging stock market companies hosted by First Securities.
2022.06.05
Our company's long-acting analgesic injection, Naldebain, has obtained import drug approval in Malaysia.
2022.04.12
Supplementary Announcement Regarding the Board of Directors' Resolution to Convene the 2022 Annual General Meeting of Shareholders
2022.04.12
Announcement of the Company's Board of Directors' Resolution to Transfer Surplus to Capital Increase and Issue New Shares
2022.03.02
Announcement: The company's board of directors has approved the change of general manager
2022.03.02
The Board of Directors of the Company has approved the proposal for the Chairman to concurrently serve as CEO
2022.03.02
The company's board of directors has approved the promotion of key operational executives
2022.03.02
Announcement: The company's board of directors has approved the ratification of the appointment of the head of research and development
2022.03.02
Announcement of the Board of Directors' resolution to convene the 2022 Annual General Meeting of Shareholders
2021.12.29
Our company's long-acting analgesic injection, Naldebain, has obtained import drug approval in Thailand
2021.08.12
Announcement of the Board of Directors' resolution regarding matters related to the ex-rights date in 2021
2021.08.12
Announcement of the Board of Directors' resolution to apply for listing of the company's shares on the Emerging Stock Market
2021.08.12
The company's board of directors has resolved to establish a remuneration committee and appoint the first remuneration committee members
2021.07.28
Correction to the information disclosed in the notes to the Company’s 2020 Individual Financial Report
2021.07.15
Announcement of the resolution passed at the Company's 2021 Annual General Meeting to lift the non-compete restrictions on newly appointed directors
2021.07.15
Announcement of the list of directors (including independent directors) elected at the 2021 Annual General Meeting of Shareholders, marking one-third of the board of directors being replaced
2021.06.25
Announcement: The company's board of directors has resolved to change the date of the 2021 Annual General Meeting of Shareholders (in accordance with the Financial Supervisory Commission's announcement "Measures for Postponing Shareholders' Meetings of Publicly Listed Companies in Response to the Epidemic")
2021.05.21
The Company has suspended the scheduled shareholders' meeting in accordance with the instructions of the Financial Supervisory Commission
2021.03.09
Announcement of the Company's Board of Directors' Resolution to Transfer Surplus to Capital Increase and Issue New Shares
2021.03.09
Announcement of the Company's Board of Directors' resolution to convene the 2021 Annual General Meeting of Shareholders
2020.12.16
Our company's long-acting analgesic injection, Naldebain, has obtained import drug approval from the Singapore HSA